Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery
Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]
Driving the Discovery and Clinical Development of the Next Generation of Alzheimer’s Disease Drugs: Join us at the CNS Summit 2023
We are thrilled to announce that Aitia will be participating in the CNS Summit 2023 conference. Colin Hill, will be joined by Rudolph Tanzi, Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, and Ole Isacson, Professor & Chair […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]
Leveraging AI in Healthcare and Life Sciences Discussion: Join our CEO, Colin Hill at the Sixth Annual International IP Summit
We are delighted to announce that Aitia will be participating in the Sixth Annual International IP Summit. Our CEO, Colin Hill, will be a featured speaker at an engaging discussion titled: Leveraging AI in Healthcare and Life Sciences: Key Legal Considerations. Colin will be joined by industry experts Dr. Bernardo Bizzo, the Senior Director of […]
A Digital Boost for Pharmaceutical R&D: Join our CEO, Colin Hill at the Orion Day in Finland
We are thrilled to announce that Aitia will be participating at the Orion Day conference. Our CEO, Colin Hill, will be giving a keynote titled: AI-Powered Digital Twins: Revolutionizing Pharmaceutical Drug Discovery and Clinical Development to Create the Next Generation of Breakthrough Drugs. During the keynote, Colin will share valuable insights and engage in a dynamic […]
Accelerating Drug Target Identification and Validation with AI and Digital Twins: Join our CBO, Joseph Donahue at BioTechX Europe 2023
We are thrilled to announce that Aitia will be participating in Basel at the BioTechX Europe 2023 conference. Our CBO, Joseph Donahue, will be taking the stage in the AI in Drug Development and Discovery session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share valuable insights on harnessing Causal AI and Digital […]
CEO and Investor Roundtable Discussion: Join our CEO, Colin Hill at BioCentury East-West Pharma Summit 2023
We are delighted to announce that Aitia will be participating in the prestigious global East-West Pharma Summit 2023 conference. Our CEO, Colin Hill, will be a featured speaker at a roundtable discussion along with industry experts Christine Aylward, the Founding & Managing Partner of Magnetic Ventures, Nathalie Beslay, the Co-founder of NAAIA, Michelle Chen, PH.D., […]
Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease
Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers. In […]